Pharmacovigilance drug form continues to reduce drug costs and prescribing drugs not subject to use review, according to minutes of a meeting released Tuesday by the Workers Compensation Insurance Ratings Bureau's actuarial committee review of the form in December.
evaluation of the form's impact on drug use in the state – focused on figures before the pandemic – revealed that workers' compensation for drug costs has continued to decrease since the implementation of the form on 1 January 2018, but at a slower pace until 2019 and the period before COVID 19 2020.
The proportion of prescribed drugs that are not subject to use review also continued to increase, and the proportion of payments for opioids, compounds and branded drugs with generic alternatives also continued to decrease in the state.
However, the review noted that the share of payments for medicines dispensed increased slightly at the end of 201
Overall, the Committee noted that the continued reduction in drug costs suggests that the form "achieves the intended effects."
More insurance and work compensation news about coronavirus crisis here . Catalog